scholarly journals Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients

Oncotarget ◽  
2018 ◽  
Vol 9 (27) ◽  
pp. 19283-19293 ◽  
Author(s):  
Afroditi Nanou ◽  
Frank A.W. Coumans ◽  
Guus van Dalum ◽  
Leonie L. Zeune ◽  
David Dolling ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1188
Author(s):  
Athina Markou ◽  
Eleni Tzanikou ◽  
Areti Strati ◽  
Martha Zavridou ◽  
Sophia Mastoraki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
High Frequency ◽  
Tumor Biomarker ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Promising Target

PIM-1 is an oncogene involved in cell cycle progression, cell growth, cell survival and therapy resistance, activated in many types of cancer, and is now considered as a very promising target for cancer therapy. We report for the first time that PIM-1 is overexpressed in circulating tumor cells (CTCs) from metastatic castration-resistant prostate cancer patients (mCRPC). We first developed and validated a highly sensitive RT-qPCR assay for quantification of PIM-1 transcripts. We further applied this assay to study PIM-1 expression in EpCAM(+) CTC fraction isolated from 64 peripheral blood samples of 50 mCRPC patients. CTC enumeration in all samples was performed using the FDA-cleared CellSearch® system. PIM-1 overexpression was detected in 24/64 (37.5%) cases, while in 20/24 (83.3%) cases that were positive for PIM-1 expression, at least one CTC/7.5 mL PB was detected in the CellSearch®. Our data indicate that PIM-1 overexpression is observed at high frequency in CTCs from mCRPC patients and this finding, in combination with androgen receptor splice variant 7 (AR-V7) expression in CTCs, suggest its potential role as a very promising target for cancer therapy. We strongly believe that PIM-1 overexpression in EpCAM(+) CTC fraction merits to be further evaluated and validated as a non-invasive circulating tumor biomarker in a large and well-defined patient cohort with mCRPC.

Sign in / Sign up

Export Citation Format

Share Document